BASF and Biomillenia join forces in microbiome research to promote healthy skin

7 Oct 2019

Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.

BASF and Biomillenia have signed a microbiome discovery agreement, which aims to identify novel dermocosmetic active ingredients involved in promoting skin health.

BASF and Biomillenia join forces in microbiome research to promote healthy skin

The French company Biomillenia will contribute its unique microbiome-on-a-chip technology that has the ability to grow specific microbes and maintain a higher diversity of living microbes than with standard microbiology methods. It will allow BASF to explore how active ingredients can modulate the presence and growth of the skin microbiota, and consequently affect its health. By bringing together interdisciplinary know-how from within the company as well as from external partners, BASF constantly expands its activities dedicated to developing solutions acting on or through the skin microbiota. “The skin hosts a huge and varied microbiota and as such plays an important role in skin health. Biomillenia’s ability to rapidly identify novel microbes and screen for active ingredients involved in promoting healthy skin will enable new research possibilities and market opportunities for BASF,” said David Hérault, R&D Global Director of BASF Beauty Care Solutions. “The microbiome is a vast natural pool of mostly undiscovered microbes that can be leveraged across several industries, including consumer health, agriculture, animal health and food. We are supporting companies in these sectors by providing access to our technology platform to culture and perform functional analysis of microbes in low volume droplets using proprietary lab-on-a-chip technology. In addition, our customers can gain access to our microbial culture collection and state of the art microbe isolation and sequencing technologies,” said Dirk Loeffert, Ph.D., CEO of Biomillenia.

Read More

Related news

Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD

Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD

21 Feb 2020

Beovu is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on 3-month dosing intervals immediately after the loading phase.

Read more 
Catalent to manufacture first-in-class mAb targeting solid tumours

Catalent to manufacture first-in-class mAb targeting solid tumours

11 Feb 2020

ZM008 could have potential benefits for the treatment of prostate cancer.

Read more 
BD completes clinical trial for its wearable injector

BD completes clinical trial for its wearable injector

11 Feb 2020

The pre-filled, pre-assembled injector is designed to prioritize safety, convenience and usability while delivering high-value drug treatments in the comfort of an in-home environment.

Read more 
New Velesco Pharma clinical manufacturing facility begins operations

New Velesco Pharma clinical manufacturing facility begins operations

5 Feb 2020

The facility will triple the company’s cGMP clinical trial manufacturing capacity.

Read more 
Inovio and Beijing Advaccine to advance vaccine against Coronavirus

Inovio and Beijing Advaccine to advance vaccine against Coronavirus

30 Jan 2020

Agreement will facilitate clinical trial translations in China.

Read more 
First human trial of monoclonal antibody to prevent malaria opens

First human trial of monoclonal antibody to prevent malaria opens

28 Jan 2020

If proven safe and effective, mAb CIS43LS might be used prophylactically by tourists, medical workers or military personnel who travel to areas where malaria is common.

Read more 
Thermo launches next-generation, compressor-free plate sealer

Thermo launches next-generation, compressor-free plate sealer

28 Jan 2020

Features new functionalities and capabilities making it versatile for a variety of both manual and automated microplate processing life science applications.

Read more 
Merck invests in biotech development facility in Switzerland

Merck invests in biotech development facility in Switzerland

27 Jan 2020

€250 million to be invested during the 2019-2022 period in new facility bridging research and manufacturing.

Read more 
Grey Wolf Therapeutics secures funding for cancer therapies development

Grey Wolf Therapeutics secures funding for cancer therapies development

21 Jan 2020

The company targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumours for attack and destruction by the immune system.

Read more 
Diabetes diagnosis - now a matter of sweat and tears?

Diabetes diagnosis - now a matter of sweat and tears?

21 Jan 2020

No need to draw blood; researchers develop smart technology to diagnose diabetes and treat diabetic retinopathy.

Read more